News

orange__line
POST ASCO GU 2019

The MedSIR Project Development team attended the 2019 Genitourinary (GU) Cancers Symposium held in San Francisco, CA on February 14-16. It was a great opportunity to meet our scientific collaborators, business partners, and friends...
READ MORE...
MedSIR will attend The BCC 2019

We are very happy to announce that the 16th St. Gallen International Breast Cancer Conference will be held in Vienna, Austria, better known as “the city of dreams" or “city of music” from March 20-23, 2019. Vienna is...
READ MORE...
ASCO-GU
MedSIR is back to San Francisco for ASCO GU 2019

MedSIR will attend the Genitourinary Cancers Symposium (ASCO GU) for the second time in a row. The GU Symposium, now in its 15th year, will take place in San Francisco, CA from February...
READ MORE...
PREPARATORY PROJECTS FOR H2020 PROPOSALS (HORIZONTE-CV)

MEDICA SCIENTIA INNOVATION RESEARCH SL, has received financial support from IVACE through the HORIZONTE-CV Program and financial support from the European...
READ MORE...
The MERIBEL Trial

Since it was founded in 2012, MedSIR embarked on a journey to improve the lives of cancer patients through the design of clinically relevant trials. One of the first steps was the MERIBEL trial and we are pleased to announce that the results of this study...
READ MORE...
We want to announce a substudy proposal!

About 14,69% of patients screened for PHERGain study had failed to enter because of non-measurable disease by Positron Emission Tomography (PET) criteria (PERCIST). Early PET-SCAN evaluation has shown...
READ MORE...
Another big step in PHERGAIN Study

We are glad to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy...
READ MORE...
MedSIR will be at 41st Annual San Antonio Breast Cancer Symposium (SABCS)

MedSIR will be attending this 41st Annual event from December 04 - 08, 2018 at Henry B. Gonzalez Convention Center, San Antonio, Texas, USA. We are very excited to be part of...
READ MORE...
100% Recruitment Achieved of EXCAAPE Study!

We are pleased to announce that EXCAAPE study "A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression...
READ MORE...